Gilead Breaks Ground on Pharmaceutical Development & Manufacturing Technical Development Center

Gilead Sciences has broken ground on its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters.

This milestone is part of Gilead’s planned $32 billion investment in U.S. innovation through 2030. This investment is projected to generate more than $43 billion in economic value nationwide, strengthening America’s biopharmaceutical leadership while fueling jobs, research, and domestic manufacturing.

“This new facility is part of our vision for delivering next generation therapies and a cornerstone of Gilead’s $32 billion investment commitment in the United States,” said Daniel O’Day, Chairman and CEO of Gilead Sciences. “We have multiple construction projects underway, all of which will generate thousands of American jobs and help to drive U.S. leadership in global biopharma innovation.”

The five-story, 180,000 square foot facility will serve as a hub for innovation and collaboration across technical development and manufacturing teams. Designed with flexible pilot lab space and advanced digital infrastructure, the NTDC will accelerate technology transfer and support the advancement of next-generation biologics across Gilead’s pipeline. It will feature digitally enabled systems, autonomous robotics, and real-time digital monitoring, making it one of the most AI-enabled centers in the biopharma industry.

In addition to the NTDC, the company is currently developing two other facilities at the Foster City headquarters: a new research building designed to accelerate scientific discovery, already under construction, and a biologics manufacturing facility that will expand domestic production capacity. These current investments further build on Gilead’s strong history of U.S. investment, with more than $15 billion over the last decade. Together, these investments form an integrated innovation ecosystem designed to accelerate discovery, streamline manufacturing, and reinforce Gilead’s role as a U.S.-based biopharma leader.

The groundbreaking event featured remarks from Gilead leadership, including Daniel O’Day, CEO; Stacey Ma, Executive Vice President of Pharmaceutical Development and Manufacturing; and Joydeep Ganguly, Senior Vice President of Corporate Operations. Distinguished guests included:

• California Lieutenant Governor Eleni Kounalakis
• Rosanne Foust and Larisa Ocanada, San Mateo County Economic Development Association
• Tim Scott, CEO of Biocom
• Supervisor Noelia Corzo, San Mateo County Board of Supervisors